Literature DB >> 24836395

Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis.

P Valent1, L Escribano, S Broesby-Olsen, K Hartmann, C Grattan, K Brockow, M Niedoszytko, B Nedoszytko, J N G Oude Elberink, T Kristensen, J H Butterfield, M Triggiani, I Alvarez-Twose, A Reiter, W R Sperr, K Sotlar, S Yavuz, H C Kluin-Nelemans, O Hermine, D Radia, J J van Doormaal, J Gotlib, A Orfao, F Siebenhaar, L B Schwartz, M Castells, M Maurer, H-P Horny, C Akin, D D Metcalfe, M Arock.   

Abstract

Mastocytosis is an emerging differential diagnosis in patients with more or less specific mediator-related symptoms. In some of these patients, typical skin lesions are found and the diagnosis of mastocytosis can be established. In other cases, however, skin lesions are absent, which represents a diagnostic challenge. In the light of this unmet need, we developed a diagnostic algorithm for patients with suspected mastocytosis. In adult patients with typical lesions of mastocytosis in the skin, a bone marrow (BM) biopsy should be considered, regardless of the basal serum tryptase concentration. In adults without skin lesions who suffer from mediator-related or other typical symptoms, the basal tryptase level is an important parameter. In those with a slightly increased tryptase level, additional investigations, including a sensitive KIT mutation analysis of blood leucocytes or measurement of urinary histamine metabolites, may be helpful. In adult patients in whom (i) KIT D816V is detected and/or (ii) the basal serum tryptase level is clearly increased (>25-30 ng/ml) and/or (iii) other clinical or laboratory features suggest the presence of 'occult' mastocytosis or another haematologic neoplasm, a BM investigation is recommended. In the absence of KIT D816V and other signs or symptoms of mastocytosis or another haematopoietic disease, no BM investigation is required, but the clinical course and tryptase levels are monitored in the follow-up. In paediatric patients, a BM investigation is usually not required, even if the tryptase level is increased. Although validation is required, it can be expected that the algorithm proposed herein will facilitate the management of patients with suspected mastocytosis and help avoid unnecessary referrals and investigations.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  KIT D816V; diagnostic algorithm; mast cells; mastocytosis; tryptase

Mesh:

Year:  2014        PMID: 24836395     DOI: 10.1111/all.12436

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  34 in total

1.  Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications.

Authors:  Maria Jara-Acevedo; Cristina Teodosio; Laura Sanchez-Muñoz; Ivan Álvarez-Twose; Andrea Mayado; Carolina Caldas; Almudena Matito; José M Morgado; Javier I Muñoz-González; Luis Escribano; Andrés C Garcia-Montero; Alberto Orfao
Journal:  Mod Pathol       Date:  2015-06-12       Impact factor: 7.842

2.  A distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis.

Authors:  Melody C Carter; Avanti Desai; Hirsh D Komarow; Yun Bai; Sarah T Clayton; Alicia S Clark; Karina N Ruiz-Esteves; Lauren M Long; Daly Cantave; Todd M Wilson; Linda M Scott; Olga Simakova; Mi-Yeon Jung; Jamie Hahn; Irina Maric; Dean D Metcalfe
Journal:  J Allergy Clin Immunol       Date:  2017-06-16       Impact factor: 10.793

3.  Identification of alpha-gal sensitivity in patients with a diagnosis of idiopathic anaphylaxis.

Authors:  M C Carter; K N Ruiz-Esteves; L Workman; P Lieberman; T A E Platts-Mills; D D Metcalfe
Journal:  Allergy       Date:  2017-12-27       Impact factor: 13.146

Review 4.  Hymenoptera Anaphylaxis and C-kit Mutations: An Unexpected Association.

Authors:  Patrizia Bonadonna; Massimiliano Bonifacio; Carla Lombardo; Roberta Zanotti
Journal:  Curr Allergy Asthma Rep       Date:  2015-08       Impact factor: 4.806

Review 5.  Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis.

Authors:  John H Baird; Jason Gotlib
Journal:  Curr Hematol Malig Rep       Date:  2018-10       Impact factor: 3.952

Review 6.  Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis.

Authors:  M Rossini; R Zanotti; G Orsolini; G Tripi; O Viapiana; L Idolazzi; A Zamò; P Bonadonna; V Kunnathully; S Adami; D Gatti
Journal:  Osteoporos Int       Date:  2016-02-18       Impact factor: 4.507

Review 7.  [Mastocytosis : Clinical aspects, diagnostics, therapy].

Authors:  U Lippert
Journal:  Hautarzt       Date:  2017-01       Impact factor: 0.751

Review 8.  Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future.

Authors:  Peter Valent; Cem Akin; Karin Hartmann; Gunnar Nilsson; Andreas Reiter; Olivier Hermine; Karl Sotlar; Wolfgang R Sperr; Luis Escribano; Tracy I George; Hanneke C Kluin-Nelemans; Celalettin Ustun; Massimo Triggiani; Knut Brockow; Jason Gotlib; Alberto Orfao; Lawrence B Schwartz; Sigurd Broesby-Olsen; Carsten Bindslev-Jensen; Petri T Kovanen; Stephen J Galli; K Frank Austen; Daniel A Arber; Hans-Peter Horny; Michel Arock; Dean D Metcalfe
Journal:  Cancer Res       Date:  2017-03-02       Impact factor: 12.701

9.  Osteoporosis Caused by Systemic Mastocytosis: Prevalence in a Cohort of 8392 Patients with Osteoporosis.

Authors:  Martin Gehlen; Niels Schmidt; Michael Pfeifer; Subathira Balasingam; Michael Schwarz-Eywill; Anna Maier; Mathias Werner; Heide Siggelkow
Journal:  Calcif Tissue Int       Date:  2021-07-05       Impact factor: 4.333

Review 10.  KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis.

Authors:  M Arock; K Sotlar; C Akin; S Broesby-Olsen; G Hoermann; L Escribano; T K Kristensen; H C Kluin-Nelemans; O Hermine; P Dubreuil; W R Sperr; K Hartmann; J Gotlib; N C P Cross; T Haferlach; A Garcia-Montero; A Orfao; J Schwaab; M Triggiani; H-P Horny; D D Metcalfe; A Reiter; P Valent
Journal:  Leukemia       Date:  2015-02-04       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.